GILD: Gilead Sciences, Inc. - Summary | Jitta

Gilead Sciences, Inc.

NASDAQ:GILD

Price
$63.19
Loss Chance
47.4%
4.50JITTA SCORE
32.68%Over Jitta Line
Jitta Ranking
159 / 871
2,268 / 4,159
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (20)
Recent Business Performance (16)
Financial Strength (68)
Return to Shareholders (88)
Competitive Advantage (36)
Jitta Signs
Return on EquityConsistently High
Dividend PayoutIncreasing Every Year
Share RepurchaseEvery Year
CapExVery Low
Interest Coverage RatioVery Good
Revenue and EarningRevenue decline from 2016-2019
Operating MarginDeclined
Recent Business PerformanceEarning decline 14.62% in the last year
SG&A to SalesIncreasing Every Year
Key Stats
Jitta Score
Jitta Line
4.50
32.68%
1.54
161.64%
2.37
346.54%
Biotechnology
6.72
28.27%
7.12
50.25%
4.44
100.00%
COMPANY DESCRIPTION
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company’s products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Second Genome; Gadeta; Carna Biosciences Inc.; Nurix Therapeutics, Inc.; Humanigen, Inc.; Kiniksa Pharmaceuticals, Ltd.; Kyverna Therapeutics, Inc.; Glympse Bio, Inc.; Renown Institute for Health Innovation; Goldfinch Bio, Inc.; Insitro, Inc.; Novo Nordisk A/S; Yuhan Corporation; Kite Pharma, Inc.; oNKo-innate Pty. Ltd.; and Roche Holding AG. The company has partnership with Arcus Biosciences, Inc. to co-develop and co-commercialize next-generation cancer immunotherapies. Gilead Sciences, Inc. was founded in 1987 and is headquartered in Foster City, California.